SBPH - Spring Bank Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
11.74
-0.16 (-1.34%)
As of 9:34AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close11.90
Open11.90
Bid0.01 x 2200
Ask14.45 x 900
Day's Range11.74 - 11.90
52 Week Range10.81 - 18.93
Volume1,870
Avg. Volume65,100
Market Cap190.013M
Beta-0.17
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.83
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventsyesterday

    Edited Transcript of SBPH earnings conference call or presentation 2-Aug-18 12:00pm GMT

    Q2 2018 Spring Bank Pharmaceuticals Inc Earnings Call

  • GlobeNewswire6 days ago

    Spring Bank Announces Pricing of Public Offering of Common Stock

    HOPKINTON, Mass. and NEW YORK, Aug. 08, 2018-- Spring Bank Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering ...

  • GlobeNewswire7 days ago

    Spring Bank Announces Proposed Public Offering of Common Stock

    Spring Bank Pharmaceuticals, Inc. (SBPH) today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.  All of the shares to be sold in the offering will be offered by Spring Bank.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.  In addition, Spring Bank intends to grant the underwriters a 30-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering. Spring Bank intends to use the net proceeds from this offering to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.

  • GlobeNewswire13 days ago

    Spring Bank Announces Positive Study Results from the Inarigivir ACHIEVE Trial

    Spring Bank Pharmaceuticals, Inc. (SBPH) today announced positive results from the third cohort (inarigivir 100mg) of Part A of the ongoing Phase 2 ACHIEVE trial.  Spring Bank also announced the expansion of the Phase 2 clinical trial being undertaken by Gilead Sciences, Inc. to include up to two additional cohorts of inarigivir co-administered with tenofovir alafenamide 25mg in chronic hepatitis B patients. Spring Bank is developing inarigivir, an orally-administered investigational selective immunomodulator, as a potential backbone in a combinatorial treatment for chronic hepatitis B virus (HBV), with a goal to accelerate and substantially increase functional cure rates in a simple, safe and selective manner. Spring Bank has already randomized the majority of the patients in the fourth and final cohort (inarigivir 200mg) of the ACHIEVE trial and anticipates that it will have top-line results by the end of 2018.

  • GlobeNewswire14 days ago

    Spring Bank Pharmaceuticals Reports Second Quarter Financial Results

    Conference Call Scheduled for Thursday, August 2 at 8:00 a.m. EDT to Provide Corporate Update. HOPKINTON, Mass., Aug. 01, 2018-- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company ...

  • GlobeNewswire3 months ago

    Spring Bank to Present at Jefferies 2018 Global Healthcare Conference

    HOPKINTON, Mass., May 29, 2018-- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases ...

  • ACCESSWIRE3 months ago

    Wired News – Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular Degeneration

    LONDON, UK / ACCESSWIRE / May 03, 2018 / Active-Investors.com has just released a free research report on Ophthotech Corp. (NASDAQ: OPHT). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OPHT as the Company's latest news hit the wire. On May 01, 2018, the New York-based biopharmaceutical Company announced that it has completed patient enrollment in its Phase-2a clinical trial of Zimura® (avacincaptad pegol) in patients with wet age-related macular degeneration (AMD).

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of SBPH earnings conference call or presentation 21-Feb-18 1:30pm GMT

    Q4 2017 Spring Bank Pharmaceuticals Inc Earnings Call

  • ACCESSWIRE6 months ago

    Spring Bank Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at ...